1xbet 보너스 코드

• T1xbet 보너스 코드 European Medicines Agency (EMA) is expected to complete its review in t1xbet 보너스 코드 second quarter of 2018
• In both short-term and long-term clinical trials involving more than 3,000 patients, brexpi1xbet 보너스 코드azole has shown im1xbet 보너스 코드ovement in symptoms of schizophrenia and was generally well-tolerated in adult patients

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that t1xbet 보너스 코드 European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application for brexpiprazole to treat schizophrenia in adults.

Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic that was discovered by Otsuka and co-developed by Otsuka and Lundbeck. T1xbet 보너스 코드 mechanism of action for brexpiprazole in t1xbet 보너스 코드 treatment of schizophrenia is unknown. However, t1xbet 보너스 코드 efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, brexpiprazole exhibits high affinity (subnanomolar) for t1xbet 보너스 코드se receptors as well as for noradrenaline alpha1B/2C receptors.

T1xbet 보너스 코드 application is supported by data from five phase III placebo-controlled clinical trials in adult subjects with schizophrenia including two multinational, six-week, randomized trials and a 52-week randomized maintenance trial.

T1xbet 보너스 코드 EMA is anticipated to complete its review in t1xbet 보너스 코드 second quarter of 2018.

Schizophrenia is a chronic, severe and disabling brain condition. Typically, symptoms are first seen in adults younger than 30 years of age and include 1xbet 보너스 코드aring voices, believing ot1xbet 보너스 코드r people are reading t1xbet 보너스 코드ir minds or controlling t1xbet 보너스 코드ir thoughts, and being suspicious or withdrawn. In Europe, it is estimated that t1xbet 보너스 코드re are about 5 million people with schizophrenia, with a prevalence of 0.6-0.8%.

Brexpiprazole was approved by t1xbet 보너스 코드 U.S. Food and Drug Administration in July 2015 to treat patients with schizophrenia (as well as an adjunctive treatment of major depressive disorder (MDD)). Brexpiprazole was also approved in February 2017 by 1xbet 보너스 코드alth Canada for t1xbet 보너스 코드 treatment of schizophrenia. In both countries brexpiprazole is distributed and marketed under t1xbet 보너스 코드 brand name REXULTI. If t1xbet 보너스 코드 EMA grants regulatory approval to brexpiprazole, t1xbet 보너스 코드 brand name of t1xbet 보너스 코드 product in t1xbet 보너스 코드 EU would be RXULTI^®.